Note: This post ceased tracking COVID vaccine data on June 21, 2022
We are in the midst of the largest vaccination program in history as the world strives to move beyond the ravages of the coronavirus pandemic.
Manufacturing billions of doses and then getting them into people’s arms was always going to be a huge logistical challenge — even without the political, cultural, and economic obstacles that have made it more difficult.
In the US, COVID vaccines have become another flashpoint in the culture wars, slowing the vaccination drive. Internationally, arguments have raged over the ethics of rich countries giving booster shots while many people in the world’s poorest nations have yet to receive their first vaccine dose.
The charts and maps below will update to show the most recent vaccination data for the US and across the globe.
The first two vaccines approved for emergency use in the US in December 2020, developed by the companies Pfizer/BioNTech and Moderna, were designed to be given in two doses several weeks apart. The one-dose Johnson & Johnson vaccine was authorized for use in late February 2021. In September 2021, the FDA began authorizing booster doses, starting with people at higher risk but now recommended for much of the population as immunity from the initial shots wanes. The map above is based on total doses given, including booster shots.
Because immunity wanes slowly over time and many Americans had their initial shots in the first half of 2021, we are no longer tracking the percentage of people who are “fully vaccinated.” The US population now consists of a mix of people who have never been vaccinated, those who had their initial shots months ago but have not been recently boosted, and people who are up to date with the shots recommended for them. So there is no single number that captures how well any state or territory is doing.
Instead, this table shows two measures of immunity acquired within the last six months, either from initial shots or a booster, to allow you to compare states on how many people are likely to have better protection from serious disease. (Because boosters were not tracked by the CDC at the state level until October 2021, a small proportion of these boosters may have actually been given outside of the six-month window.)
These numbers can’t simply be added together because some people will fall into both groups: The CDC currently recommends that adults have a booster five months after completing their initial Pfizer/BioNTech or Moderna shots, or two months after receiving the Johnson & Johnson vaccine.
The table is sorted in descending order of population size. You can search or navigate through it to find out how your state or territory is doing on these measures.
This chart shows the daily number of vaccine doses given to people across the nation from the start of 2021. Because of spikes in the data due to lags in reporting, the line showing the seven-day rolling average of doses gives a clearer idea of whether vaccination is accelerating or slowing.
This map shows clearly how vaccination has lagged in the world’s poorest nations, especially in sub-Saharan Africa. “The longer vaccine inequity persists, the more the virus will keep circulating and changing, the longer the social and economic disruption will continue, and the higher the chances that more variants will emerge that render vaccines less effective,” WHO Director-General Tedros Adhanom Ghebreyesus said in September 2021.
This table shows immunity acquired in the last six months, either from the initial series of shots or through boosters, by nation. (Unlike the US CDC, Our World in Data measures boosters by doses given rather than the number of people who have received a booster. Some nations have only started recording data on booster doses in the past few months, in which case their numbers may include doses given outside of the six-month window.)
Again, the table is sorted in descending order of population size. You can search for individual nations or navigate through the table.
This chart shows the reported daily number of vaccine doses given to people across the world.
A wide variety of COVID vaccines are now in use across the world. This table shows the largest markets in which each vaccine has been authorized for use, from information compiled by the COVID-19 Vaccine Development and Approvals Tracker at McGill University in Canada, and is sorted according to the total number of approvals received by each vaccine. It includes prices from information on purchase agreements compiled by UNICEF, where available.
The vaccines from Pfizer/BioNTech and Moderna are based on a new technology that delivers a sequence of RNA that makes our own cells produce viral protein, triggering an immune response.
The drawback is that these vaccines are more expensive than those made by splicing genetic material from the coronavirus into a disabled version of another virus. Examples of such vaccines include those produced by the Anglo-Swedish company AstraZeneca, based on research from Oxford University, Johnson & Johnson, and Russia’s Gamaleya Research Institute.
Other leading vaccines are based on inactivated versions of the coronavirus, a long-standing approach to making vaccines, or subunits of viral protein. One vaccine, from the Indian company Zydus Cadila, delivers a genetic sequence that makes a viral protein inside loops of DNA.
Jeremy Singer-Vine contributed reporting for this story.
This post has been updated with with new charts to provide information on immunity acquired from recent vaccination for individual US states and nations.